Drug intelligence / Profile preview

heat-killed lactobacillus salivarius subsp. salicinius AP-32

Development stage: Preclinical
Lead developer: Glac Biotech
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Heat-killed Lactobacillus salivarius subsp. salicinius AP-32 is a postbiotic therapeutic developed by Bioflag Biotech. The active ingredient is the heat-inactivated bacterial strain *L. salivarius* subsp. *salicinius* AP-32, which was originally isolated from the healthy human gut. This biologic is formulated as oral tablets or lozenges for oral health applications. Its mechanism involves modulating the oral microbiome and local immunity by increasing salivary IgA concentration through IL-10 and TGF-beta mediated immune responses. This action helps to inhibit oral pathogens such as *Streptococcus mutans*, *Porphyromonas gingivalis*, and *Fusobacterium nucleatum*, and it has also shown activity against *Helicobacter pylori*. As a heat-killed preparation, it offers advantages over live probiotics, including enhanced stability and an improved safety profile.

Targets

TLR4 (Toll-like receptor 4)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on heat-killed lactobacillus salivarius subsp. salicinius AP-32.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on heat-killed lactobacillus salivarius subsp. salicinius AP-32.

Explore the full profile